Skip to main content
SpringerLink
Log in
Book cover

Regulatory T Cells pp 219–231Cite as

Depletion of Human Regulatory T Cells

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 707))

Abstract

Regulatory T cells (Treg) have become increasingly relevant in the study of human disease including cancer. Treg cells have been shown to inhibit anti-tumor immune responses, and elevated Treg levels have been associated with certain types of cancer. Similarly, depletion of Tregs by various methods can also enhance anti-tumor immune responses. We have found a prevalence of Treg in cancer patients when compared to normal volunteers. In addition, we have shown that the depletion of Treg using the IL-2 fusion protein denileukin diftitox decreased Treg function and increased antigen-specific T cell response to a cancer vaccine. These results indicate the potential for combining Treg depletion with anti-cancer vaccines to enhance tumor antigen-specific immune responses and the need to explore the dose and schedule of Treg depletion strategies in optimizing vaccine efforts.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Shevach, E. M., DiPaolo, R. A., Andersson, J., Zhao, D. M., Stephens, G. L., and Thornton, A. M. (2006) The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol. Rev. 212, 60–73.

    Article  PubMed  CAS  Google Scholar 

  2. Ahmad, M., Rees, R. C., and Ali, S. A. (2004) Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol. Immunother. 53, 844–854.

    Article  PubMed  Google Scholar 

  3. Terabe, M., and Berzofsky, J. A. (2004) Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 16, 157–162.

    Article  PubMed  CAS  Google Scholar 

  4. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., and Nakayama, E. (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59, 3128–3133.

    PubMed  CAS  Google Scholar 

  5. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., and Toda, M. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151–1164.

    PubMed  CAS  Google Scholar 

  6. Sakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., et al. (2001) Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182, 18–32.

    Article  PubMed  CAS  Google Scholar 

  7. Shimizu, J., Yamazaki, S., and Sakaguchi, S. (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211–5218.

    PubMed  CAS  Google Scholar 

  8. Asseman, C., Mauze, S., Leach, M. W., Coffman, R. L., and Powrie, F. (1999) An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190, 995–1004.

    Article  PubMed  CAS  Google Scholar 

  9. Lombardi, G., Sidhu, S., Batchelor, R., and Lechler, R. (1994) Anergic T cells as suppressor cells in vitro. Science 264, 1587–1589.

    Article  PubMed  CAS  Google Scholar 

  10. Seddon, B., and Mason, D. (1999) Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4(+)CD45RC- cells and CD4(+)CD8(−) thymocytes. J. Exp. Med. 189, 279–288.

    Article  PubMed  CAS  Google Scholar 

  11. Thornton, A. M., and Shevach, E. M. (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188, 287–296.

    Article  PubMed  CAS  Google Scholar 

  12. Morse, M. A., Clay, T. M., Hobeika, A. C, Osada, T., Khan, S., Chui, S., et al. (2005) Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin. Cancer Res. 15, 3017–3024.

    Article  Google Scholar 

  13. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942–949.

    Article  PubMed  CAS  Google Scholar 

  14. Liyanage, U. K., Moore, T. T., Joo, H. G., Tanaka Y., Herrmann, V., Doherty, G., et al. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756–2761.

    PubMed  CAS  Google Scholar 

  15. Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., et al. (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089–3094.

    Article  PubMed  CAS  Google Scholar 

  16. Wolf, A. M., Wolf, D., Steurer, M., Gastl, G., Gunsilius, E., and Grubeck-Loebenstein, B. (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9, 606–612.

    PubMed  Google Scholar 

  17. Viguier, M., Lemaitre, F., Verola, O., Cho, M. S., Gorochov, G., Dubertret, L., et al. (2004) Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173, 1444–1453.

    PubMed  CAS  Google Scholar 

  18. Woo, E. Y., Yeh, H., Chu, C. S., Schlienger, K., Carroll, R. G, Riley, J. L., et al. (2002) Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168, 4272–4276.

    PubMed  CAS  Google Scholar 

  19. Hussain, S. F., and Paterson, Y. (2004) CD4+CD25+ regulatory T cells that secrete TGFbeta and IL-10 are preferentially induced by a vaccine vector. J. Immunother. 27, 339–346.

    Article  PubMed  CAS  Google Scholar 

  20. Casares, N., Arribillaga, L., Sarobe, P., Dotor, J., Lopez-Diaz de Cerio, A., Melero, I., et al. (2003) CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J. Immunol. 171, 5931–5939.

    PubMed  CAS  Google Scholar 

  21. Nagai, H., Horikawa, T., Hara, I., Fukunaga, A., Oniki, S., Oka, M., et al. (2004) In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp. Dermatol. 13, 613–620.

    Article  PubMed  CAS  Google Scholar 

  22. Turk, M. J., Guevara-Patino, J. A., Rizzuto, G. A., Engelhorn, M. E., and Houghton, A. N. (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200, 771–782.

    Article  PubMed  CAS  Google Scholar 

  23. Vieweg, J., Su, Z., and Dannull, J. (2004) Enhancement of antitumor immunity following depletion of CD4+CD25+ regulatory T cells [Abstract]. J. Clin. Oncol. 2004 ASCO Annual Meeting Proceedings. 22, 2506.

    Google Scholar 

  24. Morse, M. A., Hobeika, A. C., Osada, T., Serra, D., Niedzwiecki, D., Lyerly, H. K., et al. (2008) Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112, 610–618.

    Article  PubMed  CAS  Google Scholar 

  25. Almeida, A. R., Legrand, N., Papiernik, M., and Freitas, A. A. (2002) Homeostasis of peripheral CD4+ T cells: IL-2α and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J. Immunol. 169, 4850–4860.

    PubMed  Google Scholar 

  26. Taniguchi, T., and Minami, Y. (1993) The IL-2/IL-2 receptor system: a current overview. Cell 73, 5–8.

    Article  PubMed  CAS  Google Scholar 

  27. Duvic, M., Cather, J., Maize, J., and Frankel, A. E. (1998) DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. Am. J. Hematol. 58, 87–90.

    Article  PubMed  CAS  Google Scholar 

  28. Olsen, E., Duvic, M., and Frankel, A. (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19, 376–388.

    PubMed  CAS  Google Scholar 

  29. Waters, C. A., Schimke, P. A., Snider, C. E., Itoh, K., Smith, K. A., Nichols, J. C., et al. (1990) Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur. J. Immunol. 20, 785–791.

    Article  PubMed  CAS  Google Scholar 

  30. Disis, M. L., dela Rosa, C., Goodell, V., Kuan, L. Y., Chang, J. C., Kuus-Reichel, K., et al. (2006) Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J. Immunol. Methods 308, 13–18.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Surgery, Duke University Medical Center, Durham, NC, USA

    Amy C. Hobeika, Takuya Osada & Sharon Peplinski

  2. Department of Medicine, Duke University Medical Center, Durham, NC, USA

    Michael A. Morse

  3. Department of Surgery and the Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC, USA

    H. Kim Lyerly

  4. Departments of Surgery and Immunology, Duke University Medical Center, Durham, NC, USA

    Timothy M. Clay

Authors
  1. Amy C. Hobeika
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael A. Morse
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takuya Osada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sharon Peplinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Kim Lyerly
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Timothy M. Clay
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. , Division of Immunoregulation, MRC National Institute for Medical Resea, The Ridgeway, Mill Hill, London, NW7 1AA, United Kingdom

    George Kassiotis

  2. , VIB Autoimmune Genetics Laboratory, Katholieke Universiteit Leuven, Herestraat 49, Leuven, 3000, Belgium

    Adrian Liston

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Hobeika, A.C., Morse, M.A., Osada, T., Peplinski, S., Lyerly, H.K., Clay, T.M. (2011). Depletion of Human Regulatory T Cells. In: Kassiotis, G., Liston, A. (eds) Regulatory T Cells. Methods in Molecular Biology, vol 707. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61737-979-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-61737-979-6_14

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-978-9

  • Online ISBN: 978-1-61737-979-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation